Pleuropneumonia / Pleuritis

Pleuropneumonia and pleuritis represent serious inflammatory conditions affecting the pleural space and lung tissue in horses, requiring prompt recognition and aggressive treatment to achieve favorable outcomes. Pleuropneumonia describes concurrent infection of the lung parenchyma (pneumonia) and the pleural membranes lining the chest cavity and covering the lungs (pleuritis), while pleuritis can occur independently as primary inflammation of the pleural surfaces. These conditions cause accumulation of infected or inflammatory fluid in the pleural space, compressing the lungs and severely compromising respiratory function while triggering systemic inflammatory responses that can become life-threatening.

This condition complex affects horses of all breeds and ages but demonstrates particular association with long-distance transport, earning the colloquial term shipping fever. Performance horses traveling to competitions, sale horses undergoing transport, and horses moving to new facilities face elevated risk, particularly when transport duration exceeds several hours. The stress of transport combined with head elevation that impairs normal respiratory clearance mechanisms and exposure to unfamiliar pathogens creates conditions favorable for infection development. Prevalence is highest in horses transported during warm months or under suboptimal transport conditions.

The impact of pleuropneumonia on equine health extends beyond respiratory compromise to encompass severe systemic illness with potential for life-threatening complications. Horses with significant pleural effusion experience mechanical restriction of lung expansion, causing respiratory distress that progressively worsens as fluid accumulates. The systemic inflammatory response to infection causes fever, depression, and metabolic derangements. Without aggressive treatment, pleuropneumonia carries significant mortality risk, with complications including adhesion formation, lung abscessation, and laminitis secondary to endotoxemia. Even with successful treatment, long-term consequences may include reduced athletic performance and chronic respiratory compromise.

Early detection and immediate veterinary intervention dramatically improve outcomes for horses with pleuropneumonia. This condition represents a true veterinary emergency where delays in treatment allow fluid accumulation, bacterial proliferation, and systemic inflammation to advance, making subsequent treatment more difficult and expensive while worsening prognosis. Understanding the risk factors, recognizing early warning signs, and treating aggressively from the outset provide the best opportunity for survival and return to function. Modern treatment approaches combining appropriate antimicrobials, pleural drainage, and supportive care have significantly improved survival rates compared to historical outcomes.

The primary causes of pleuropneumonia in horses involve bacterial infection reaching the lower respiratory tract through various routes. Aspiration of oropharyngeal bacteria during transport when the horse cannot lower its head is a major mechanism, allowing normal oral flora to access the lungs where they establish infection. Hematogenous spread from distant infection sites occasionally seeds the lungs and pleural space. Extension from primary pneumonia into the pleural space occurs when lung infection breaches the visceral pleura. Common bacterial isolates include Streptococcus equi subspecies zooepidemicus, Pasteurella species, Actinobacillus species, and various anaerobic bacteria, often in mixed infections.

No direct genetic predisposition to pleuropneumonia exists, though individual variation in immune competence influences susceptibility and disease severity. Horses with any form of immunosuppression, whether from concurrent disease, medication effects, or stress-related immune compromise, face increased risk when exposed to conditions favoring infection. The genetic factors influencing overall immune function may contribute indirectly to individual susceptibility, but specific hereditary links to pleuropneumonia have not been identified.

Environmental and management factors play crucial roles in pleuropneumonia development. Transport conditions represent the most significant management risk factor, particularly journeys exceeding four to six hours without rest stops allowing head lowering. Inadequate ventilation during transport increases pathogen exposure and irritant inhalation. Overcrowding at shows, sales, or training facilities exposes horses to novel pathogens. Recent viral respiratory infection damages airway defenses and predisposes to secondary bacterial invasion. Stress from any source, including training intensity, competition, weather extremes, or inadequate nutrition, compromises immune function.

Risk factors for pleuropneumonia encompass transport-related exposures, recent respiratory illness, stress, and specific management circumstances. Long-distance hauling without rest stops creates optimal conditions for aspiration and infection. Horses shipped during hot weather face compounded stress. Recent strenuous exercise before shipping may increase susceptibility. Previous respiratory tract procedures such as nasogastric intubation, dental work, or endoscopy create potential for bacterial introduction. Young performance horses in heavy training and competition face cumulative stressors that elevate risk.

The pathophysiology of pleuropneumonia begins with bacterial colonization of lung tissue, followed by inflammatory response and spread to the pleural space. Bacteria reaching the lower respiratory tract trigger neutrophil recruitment and inflammatory mediator release. As infection progresses, the visceral pleura becomes involved, and inflammatory exudate accumulates in the pleural space. This effusion initially appears serous but rapidly becomes fibrinopurulent as infection advances. Compression of functional lung tissue by accumulating fluid worsens hypoxemia. Systemic absorption of bacterial products and inflammatory mediators causes fever, toxemia, and metabolic derangements. Untreated, adhesions form between pleural surfaces, abscesses develop within lung tissue, and systemic inflammatory response syndrome may prove fatal.

Early warning signs of developing pleuropneumonia often appear subtly within days of transport or other predisposing events, requiring vigilant observation for detection. Initial symptoms may include mild depression, slight decrease in appetite, and reluctance to move freely. The horse may appear stiff or unwilling to turn sharply, reflecting early pleural pain. Mild fever may be present but can be overlooked without routine temperature monitoring. Respiratory rate may show slight elevation, though this early sign is easily missed. Any horse showing depression or decreased appetite within two weeks of transport warrants careful respiratory evaluation.

Common symptoms of established pleuropneumonia reflect both respiratory compromise and systemic illness. Fever, often high (103-106°F), develops as infection progresses. Marked depression and complete anorexia typically accompany significant disease. Respiratory rate increases substantially, often exceeding thirty breaths per minute at rest. Nostril flaring becomes apparent as respiratory effort increases. A characteristic short, shallow breathing pattern develops as horses avoid deep breaths that stretch painful pleural surfaces. Moist cough may be present, though many horses with pleuropneumonia cough less than expected due to pain inhibition.

Behavioral changes in horses with pleuropneumonia dramatically demonstrate the severity of this condition. Affected horses typically stand with elbows abducted (pointed outward) to maximize chest expansion. They resist lying down because recumbency worsens breathing difficulty and increases pleural pain. Movement becomes reluctant, and horses may refuse to walk or turn. Head and neck may extend forward to reduce airway resistance. Social withdrawal occurs as horses focus on the effort of breathing. Some horses groan audibly with respiration, reflecting pleural pain.

Physical signs of pleuropneumonia provide diagnostic clues during veterinary examination. Auscultation reveals absent or markedly diminished breath sounds ventrally where fluid has accumulated, with harsh or increased sounds dorsally over remaining aerated lung. A fluid line may be detectable where normal sounds transition to silence. Percussion produces dullness over fluid-filled regions. Bilateral involvement is common, though asymmetric fluid accumulation frequently occurs. Digital pressure between ribs may elicit pain response. Peripheral edema, particularly ventral edema along the chest and abdomen, develops in some cases due to protein loss and inflammation.

Symptom progression in untreated pleuropneumonia follows an alarming trajectory over hours to days. Initial mild signs rapidly worsen as fluid accumulates and systemic illness advances. Respiratory distress intensifies, with horses eventually demonstrating open-mouth breathing and extreme anxiety. Fever may spike higher or, ominously, decrease as septic shock develops. Cyanotic mucous membranes indicate severe hypoxemia. Weight shifts frequently as the horse struggles to find comfortable positions. Without intervention, cardiovascular collapse and death occur in severe cases, sometimes within days of symptom onset.

Emergency symptoms requiring immediate veterinary attention include severe respiratory distress with visible rib and abdominal movement during breathing, open-mouth breathing, cyanotic or muddy-colored mucous membranes, extreme depression or weakness approaching collapse, high fever exceeding 105°F, and any signs suggesting laminitis such as shifting weight or reluctance to move. These signs indicate advanced disease requiring emergency intervention including pleural drainage, intensive antimicrobial therapy, and supportive care. Transport to a referral hospital may be necessary for horses requiring chest drain placement and intensive monitoring.

Physical examination of horses with suspected pleuropneumonia combines thorough respiratory assessment with evaluation of systemic health status. The veterinarian observes respiratory rate, effort, and pattern, noting characteristic shallow breathing and abducted elbow posture. Auscultation of the thorax systematically evaluates all lung fields, identifying areas of absent breath sounds ventrally that suggest fluid accumulation and remaining aerated lung dorsally. Percussion may detect fluid lines. Rebreathing examination using a plastic bag briefly increases respiratory depth, accentuating abnormal sounds and sometimes triggering coughing. Temperature measurement, mucous membrane evaluation, and assessment of hydration status characterize systemic involvement.

Diagnostic testing for pleuropneumonia confirms pleural effusion, identifies causative organisms, and assesses severity. Complete blood count typically reveals marked leukocytosis with neutrophilia and often a left shift, indicating active bacterial infection. Hyperfibrinogenemia reflects inflammation. Serum chemistry identifies electrolyte abnormalities, azotemia from dehydration, and hypoalbuminemia from protein loss into pleural fluid. Arterial blood gas analysis quantifies hypoxemia severity. Thoracic radiography, when feasible, demonstrates fluid lines, pulmonary infiltrates, and sometimes gas pockets suggesting anaerobic infection. Thoracic ultrasound provides excellent characterization of fluid volume, character, and distribution, and guides thoracocentesis.

Thoracocentesis, aspiration of pleural fluid, represents both a diagnostic and therapeutic procedure in pleuropneumonia. Ultrasound-guided needle placement minimizes complications and ensures fluid collection. Evaluation of fluid character provides immediate diagnostic information, with septic effusions appearing cloudy, malodorous, and containing fibrin. Laboratory analysis measures protein content, cell counts, and glucose levels. Bacterial culture and sensitivity testing identify causative organisms and guide antimicrobial selection, though mixed infections complicate interpretation. Cytological examination reveals degenerate neutrophils and may show intracellular bacteria.

Differential diagnosis for pleuropneumonia includes other causes of respiratory distress and pleural effusion. Neoplastic conditions, particularly lymphoma, can produce pleural effusion. Congestive heart failure causes transudative effusion without infection. Hemothorax from trauma or coagulopathy presents similarly but with bloody fluid. Diaphragmatic hernia may be associated with effusion and respiratory compromise. Simple pneumonia without pleural involvement causes respiratory signs but lacks fluid accumulation. Thorough diagnostic evaluation distinguishes these conditions, with ultrasound and fluid analysis providing key differentiating information.

Emergency treatment for pleuropneumonia begins immediately upon diagnosis, as delays worsen outcome. Intravenous fluid therapy addresses dehydration and supports cardiovascular function while providing a vehicle for medication administration. Broad-spectrum intravenous antimicrobials targeting both aerobic and anaerobic bacteria start immediately, with subsequent adjustments based on culture results. Common initial choices include combinations of penicillin, gentamicin, and metronidazole, or newer single agents with appropriate spectrum. Nonsteroidal anti-inflammatory drugs reduce fever, provide analgesia, and limit systemic inflammation. Thoracocentesis for large effusions provides immediate respiratory relief by removing compressive fluid.

Medical management of pleuropneumonia extends over weeks, requiring sustained therapeutic commitment. Antimicrobial therapy continues for prolonged periods, typically four to six weeks minimum, with duration guided by clinical response and monitoring parameters. Serial ultrasound examinations track fluid reaccumulation and guide repeat drainage. Intravenous therapy transitions to oral antimicrobials when the horse stabilizes and oral options with appropriate spectrum are identified. Supportive care includes nutritional support, maintaining hydration, and monitoring for complications. Plasma transfusion may benefit horses with severe hypoalbuminemia or to provide passive immunity.

Surgical intervention becomes necessary when medical management alone proves insufficient. Indwelling chest drains (thoracostomy tubes) allow continuous or intermittent drainage of rapidly accumulating or loculated fluid. Thoracoscopy enables visualization of the pleural space, breakdown of adhesions, and targeted lavage. Standing thoracotomy with rib resection provides access for removal of organized fibrinous material that cannot drain through tubes. Lung abscess drainage may be performed in selected cases. These procedures require specialized facilities and carry risks but may be life-saving for horses with severe or complicated disease.

Supportive care optimization maximizes recovery potential alongside specific antimicrobial and drainage therapy. Nutritional support ensures adequate caloric and protein intake during prolonged illness, potentially requiring assisted feeding techniques. Environmental management places horses in well-ventilated, comfortable housing that minimizes stress. Restricted exercise reduces oxygen demand during the acute phase. Monitoring for laminitis, a devastating complication of systemic inflammation and endotoxemia, requires regular hoof evaluation and potentially prophylactic measures such as cryotherapy. Thrombophlebitis prevention and management addresses complications from prolonged intravenous catheterization.

Rehabilitation following successful treatment of pleuropneumonia extends over months as lung tissue heals and respiratory capacity recovers. Exercise restriction continues until clinical signs resolve, diagnostic markers normalize, and repeat imaging shows resolution of effusion and pulmonary changes. Gradual reintroduction of exercise begins with hand walking, progressing to light under-saddle work, with careful monitoring for exercise intolerance or recurring respiratory signs. Serial recheck examinations confirm continued improvement and guide activity advancement. Full return to previous performance levels may require six months or longer in severe cases.

Treatment decisions for pleuropneumonia consider severity, complications, financial constraints, and individual horse factors. Mild cases detected early may respond to outpatient antimicrobial therapy with careful monitoring. Moderate to severe cases require hospitalization for intensive management. Horses developing complications such as pulmonary abscessation, severe adhesions, or laminitis face guarded prognosis and may require prolonged, expensive treatment with uncertain outcome. Discussion with owners regarding realistic expectations, treatment costs, and quality of life considerations guides decision-making when complications arise or response proves inadequate.

Recovery timelines for pleuropneumonia vary substantially based on initial disease severity, complications, and treatment response. Mild cases detected early and treated aggressively may show clinical improvement within one to two weeks, though complete resolution of all abnormalities requires four to six weeks of continued therapy. Moderate cases typically require one to two months of active treatment followed by additional convalescence. Severe or complicated cases may need three to six months before return to work, and some horses never regain full athletic capacity. The extended recovery period reflects the slow resolution of pleural changes and restoration of normal respiratory function.

Post-treatment care and monitoring continue well beyond resolution of acute clinical signs. Regular veterinary recheck examinations assess recovery progress through physical examination, ultrasonography, and potentially bloodwork. Serial thoracic ultrasound documents resolution of pleural effusion and identifies any residual abnormalities such as pleural thickening or loculated fluid pockets. Complete blood count and fibrinogen levels track resolution of inflammation. Exercise tolerance evaluation guides return to work decisions. Monitoring continues monthly to bimonthly until all parameters normalize.

Prognosis for pleuropneumonia correlates strongly with disease severity at presentation, promptness of treatment, and development of complications. Horses with unilateral disease, smaller effusion volumes, and rapid response to initial therapy carry favorable prognosis for survival and return to function. Bilateral disease, massive effusions, abscessation, and development of laminitis or other systemic complications significantly worsen prognosis. Early, aggressive treatment dramatically improves outcomes compared to delayed or inadequate intervention. Overall survival rates in referral hospital populations range from sixty to eighty percent, with athletic function recovery somewhat lower.

Long-term soundness and performance outlook for pleuropneumonia survivors depends on residual pleural and pulmonary changes. Many horses recover completely and return to previous performance levels without limitation. Others develop pleural adhesions that restrict lung expansion, causing varying degrees of exercise intolerance. Residual pulmonary fibrosis from resolved infection or abscessation may permanently limit respiratory capacity. Regular athletic performance requires more complete recovery than light pleasure use, making return to high-level competition more uncertain than return to lower-demand activities.

Management practices to prevent pleuropneumonia focus primarily on reducing transport-associated risk factors. Limiting transport duration to less than eight hours when possible, with rest stops every four to six hours allowing horses to lower their heads, dramatically reduces aspiration risk. Ensuring adequate trailer ventilation prevents pathogen buildup and heat stress. Avoiding transport of horses with active respiratory infections prevents progression to pleuropneumonia. Reducing overcrowding at shows and sales limits pathogen exposure. Quarantine of new arrivals protects resident horses and allows observation for developing illness.

Nutritional factors support respiratory health and immune function as protective measures against pleuropneumonia. Horses maintained in optimal body condition with balanced nutrition mount more effective immune responses to bacterial challenge. Adequate protein intake supports antibody production and tissue repair. Vitamin E and selenium, important antioxidants, may support respiratory tissue health. Avoiding nutritional stress during transport through appropriate feeding practices maintains immune competence. Ensuring hydration before, during, and after transport supports mucociliary clearance and overall physiological function.

Exercise and conditioning considerations influence pleuropneumonia risk through their effects on immune function and transport stress. Fit horses may tolerate transport stress with less immune compromise than poorly conditioned animals. However, avoiding intense exercise immediately before transport reduces physiological stress on the respiratory system. Allowing adequate recovery from competition before long transport gives horses opportunity to restore normal immune function. Gradual conditioning for horses new to travel helps them adapt to transport stress.

Environmental factors during transport significantly affect pleuropneumonia risk. Temperature control in trailers prevents heat stress during warm weather and excessive cold during winter. Adequate ventilation without direct drafts on horses removes airborne pathogens and ammonia while maintaining comfort. Clean trailers with fresh bedding reduce bacterial loads. Positioning horses in trailers to allow head lowering, including removing hay bags during transport for horses that will stand with elevated heads to eat, reduces aspiration risk.

Vaccination against respiratory pathogens reduces the risk of primary viral infections that predispose to secondary bacterial pleuropneumonia. Influenza and herpesvirus vaccination per recommended schedules provides relevant protection. Strangles vaccination in high-risk situations may reduce Streptococcus equi exposure. While no vaccine specifically prevents pleuropneumonia, reducing viral respiratory disease incidence indirectly protects against bacterial complications. General health maintenance including regular dental care, appropriate deworming, and prompt attention to any health issues maintains immune competence.

Daily management of horses recovering from pleuropneumonia requires attention to respiratory health, medication compliance, and gradual return to normal activity. Medication administration must maintain consistent antimicrobial levels, requiring strict adherence to prescribed schedules. Nutritional management ensures adequate intake despite reduced appetite during recovery, potentially including highly palatable feeds or supplements to encourage eating. Fresh water availability supports hydration crucial for respiratory secretion clearance. Daily monitoring of respiratory rate, effort, temperature, and appetite enables early detection of relapse or complications.

Housing and turnout considerations for pleuropneumonia recovery emphasize clean air, low stress, and appropriate activity restriction. Well-ventilated stabling with low-dust bedding protects healing respiratory tissues from additional irritation. Small paddock turnout rather than large pasture initially limits activity while providing fresh air benefits. Avoiding turnout during extreme weather reduces physiological stress. Separating recovering horses from healthy animals prevents stress from herd dynamics and protects others if any infectious risk remains. Gradual return to normal turnout accompanies clinical improvement.

Exercise modifications during pleuropneumonia recovery follow a strictly graduated approach guided by clinical status. Complete rest applies during active disease until fever resolves and respiratory comfort improves. Initial activity consists of hand walking only, beginning with short sessions and gradually extending duration. Light riding begins only after clinical examination confirms appropriate healing, typically weeks after acute illness resolution. Intensity increases gradually over months, with any recurrence of respiratory signs prompting return to lighter work. Competition-level exercise may require many months of gradual reconditioning.

Monitoring and ongoing care extend throughout the recovery period and should continue at lower intensity thereafter. Temperature monitoring daily during recovery helps detect recurring infection. Respiratory rate assessment before and after exercise identifies exercise intolerance. Regular veterinary recheck examinations verify continued improvement and detect developing complications. Monitoring for laminitis remains important during and after acute illness, particularly in horses that received corticosteroids or experienced significant systemic inflammation. Owners learn what signs warrant immediate veterinary contact.

Quality of life and use considerations guide long-term decisions for pleuropneumonia survivors. Many horses achieve complete recovery and return to previous performance levels. Others experience permanent limitations requiring career modification, moving from intense disciplines to lighter work within their respiratory capacity. Horses with significant residual compromise may be suitable only for light pleasure riding or retirement. Quality of life assessment considers not just respiratory function but overall comfort, behavior, and apparent wellbeing. Regular veterinary consultation helps guide decisions about appropriate activity levels and long-term management.

Pleuropneumonia affects horses of all breeds, with risk relating primarily to management and transport factors rather than breed predisposition. However, certain breeds appear more frequently in pleuropneumonia cases due to typical use patterns rather than inherent susceptibility. Thoroughbreds and other racehorses travel extensively for racing and training, facing repeated transport-associated risk. Warmbloods, sport horses, and other competition breeds similarly experience frequent transport to shows and events. Quarter Horses traveling to reining, cutting, and other stock horse competitions face transport exposure. Any breed can develop pleuropneumonia given appropriate exposure circumstances.

Use and discipline considerations strongly influence pleuropneumonia risk through their effects on transport frequency and conditions. Racehorses traveling long distances to racetracks, often under time pressure that discourages rest stops, face particularly high risk. Show horses with frequent travel to competitions accumulate exposure over time. Sale horses undergoing transport to auctions experience stress and crowding that elevate risk. Event horses traveling to competitions with strenuous cross-country phases face combined transport and exercise stress. Horses in any discipline requiring long-distance transport deserve careful attention to prevention measures.

No genetic testing relates to pleuropneumonia risk, as the condition lacks hereditary components. Breeding recommendations focus on management rather than genetics, emphasizing transport practices, biosecurity, and general health maintenance for breeding stock and young horses. Broodmares traveling to stallion stations face transport-associated risks similar to performance horses. Young horses shipped to training facilities or sales face their first significant transport exposure, potentially without established immunity to pathogens encountered. Breeding operations benefit from implementing transport protocols and biosecurity measures that protect all horses regardless of breeding considerations.

Pleuropneumonia commonly co-occurs with or leads to several related conditions affecting respiratory and systemic health. Lung abscessation develops when pulmonary infection becomes walled-off, creating pockets of purulent material that resist antimicrobial penetration and require prolonged treatment. Laminitis represents a devastating complication of systemic inflammation and endotoxemia associated with severe pleuropneumonia. Thrombophlebitis of jugular veins results from prolonged intravenous catheterization necessary for treatment. Colitis may develop from antimicrobial-associated disruption of gastrointestinal flora.

Conditions with similar symptoms to pleuropneumonia require differentiation through diagnostic testing. Primary pneumonia without pleural involvement causes fever, depression, and respiratory signs but lacks pleural effusion. Neoplasia, particularly lymphoma, can cause pleural effusion and respiratory compromise without infection. Congestive heart failure produces pleural and pericardial effusion from cardiac dysfunction. Ruptured diaphragm with abdominal organs entering the thorax causes severe respiratory compromise. Botulism can cause respiratory difficulty from neuromuscular weakness. Thorough diagnostic evaluation including ultrasonography, fluid analysis, and systemic assessment distinguishes these conditions.

Potential complications of pleuropneumonia beyond those commonly seen include pericarditis from extension of infection to the pericardial sac, bronchopleural fistula allowing communication between airways and pleural space, constrictive pericarditis from healing pericardial involvement, and chronic obstructive pulmonary disease-like syndrome from permanent airway changes. Severe adhesion formation may lead to a fibrothorax that permanently restricts lung expansion. Recognition of complications early allows treatment modification and appropriate prognostic discussions with owners facing extended treatment courses with uncertain outcomes.